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Abstract
Background SPD489-404 was the first 2-year safety study
of lisdexamfetamine dimesylate in the treatment of atten-
tion-deficit/hyperactivity disorder in children and adoles-
cents. In accordance with advice from the European
Medicines Agency, assessment of cognitive function was a
predefined safety outcome in SPD489-404.
Objective The objective of this study was to assess cog-
nitive function over 2 years in study SPD489-404, using
the Cambridge Neuropsychological Test Automated Bat-
tery (CANTAB).
Methods Participants aged 6–17 years received dose-opti-
mised open-label lisdexamfetamine dimesylate (30, 50 or
70 mg/day) for 104 weeks. Cognition was assessed using
four CANTAB tasks; Delayed Matching to Sample (DMS),
Spatial Working Memory (SWM), Stop Signal Task (SST)
and Reaction Time (RTI). Key and additional variables
were pre-specified for each CANTAB task; groupwise
mean percentage changes in key variables from baseline
of[5% were considered potentially clinically significant.
Results All 314 enrolled participants received lisdexam-
fetamine dimesylate and were included in the safety pop-
ulation, and 191 (60.8%) completed the study. No
potentially clinically significant deteriorations from base-
line were observed in any key CANTAB variable over the
2 years of the study. Based on predefined thresholds,
potentially clinically significant improvements from base-
line were observed at 6 months (DMS median reaction
time, mean per cent change, - 6.6%; SWM total between-
search errors, - 22.8%; SST stop signal reaction time,
–18.9%), and at the last on-treatment assessment (DMS
median reaction time, - 6.5%; SWM total between-search
errors, - 32.6%; SST stop signal reaction time, - 25.7%).
Conclusions Lisdexamfetamine dimesylate treatment for
2 years was not associated with deterioration of cognitive
function in children and adolescents with attention-deficit/
hyperactivity disorder. Although improvements in some
cognitive measures were observed, lack of a control group
makes interpretation of the findings difficult. Further
studies of the impact of stimulants on cognition are
required.
ClinicalTrials.gov identifier NCT01328756.
This article discusses data derived from a study described in an article
available at https://doi.org/10.1007/s40263-017-0443-y.
Electronic supplementary material The online version of this
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Key Points
Lisdexamfetamine dimesylate is a stimulant used to
treat children, adolescents and adults with attention-
deficit/hyperactivity disorder.
SPD489-404 was a 2-year safety study of
lisdexamfetamine dimesylate in children and
adolescents with attention-deficit/hyperactivity
disorder in which cognitive function was assessed
using the Cambridge Neuropsychological Test
Automated Battery (CANTAB).
In this study, lisdexamfetamine dimesylate treatment
was not found to be associated with cognitive
impairment; possible improvements in some
domains of cognitive function were observed.
1 Introduction
The prodrug stimulant lisdexamfetamine dimesylate (LDX)
is indicated to treat attention-deficit/hyperactivity disorder
(ADHD) in children, adolescents and adults [1]. The effi-
cacy of LDX in relieving the symptoms of ADHD has been
demonstrated in a series of pivotal randomised controlled
trials in North America and Europe [2–5]. In addition, a
large body of evidence from trials of at least 12 months’
duration indicates that the safety and tolerability profile of
LDX is similar to that of other stimulants in people with
ADHD [1, 6, 7]. A rapid return of symptoms following
LDX withdrawal was observed in a randomised withdrawal
study, demonstrating the need for continued treatment to
maintain efficacy [8]. SPD489-404 was the first 2-year
open-label safety study of LDX in children and adolescents
with ADHD [9]. Over the duration of the study, treatment-
emergent adverse events were reported in line with
expectations for the stimulant class of ADHD medication,
with decreased appetite, weight decrease, insomnia and
headache being among the most common. The incidence of
these common treatment-emergent adverse events peaked
early in the study and declined thereafter [9].
Attention-deficit/hyperactivity disorder is characterised
by the symptoms of inattention and/or hyperactivity-im-
pulsivity, and by functional impairment. Impaired cogni-
tive development is also reported to be associated with
ADHD [10–12]. The domains of cognitive function that are
often impaired in ADHD include those relating to execu-
tive functions, such as impulse control and working
memory, as well as non-executive functions, such as
memory and reaction time [10]. There are little data
available on the cognitive effects of extended treatment
with psychostimulants. Following a literature review that
identified associations between methylphenidate therapy
and cognition and/or motivation, Kovshoff et al. conducted
a semi-structured interview in a sample enriched for such
experiences, including children and adolescents with
ADHD, clinicians, carers and teachers. Respondents most
commonly cited problems with attention/concentration,
with patients describing ‘zoning out’ and ‘a tendency to
stare into space for long periods of time’ [13]. To this end,
the European Medicines Agency has advised that neu-
rocognitive assessments should be considered standard
practice in long-term studies of ADHD medications, and
that special attention should be paid to identifying potential
adverse cognitive effects [14].
The Cambridge Neuropsychological Test Automated
Battery (CANTAB), developed at the University of Cam-
bridge, UK, in the 1980s, is a computer-based cognitive
assessment system consisting of a battery of neuropsy-
chological tasks, administered via a touchscreen computer
[15]. The CANTAB tasks focus on three cognitive
domains: working memory and planning [tasks: Spatial
Span, Spatial Working Memory (SWM), Spatial Planning],
attention [tasks: Set Shifting, Reaction Time (RTI), Visual
Search] and visuospatial memory [tasks: Pattern and Spa-
tial Recognition, Delayed Matching to Sample (DMS),
Paired Associate Learning, Stop Signal Task (SST)] [16].
The CANTAB tasks have a well-established sensitivity to a
wide range of cognitive effects. In particular, results of a
meta-analysis have shown that the CANTAB is sensitive to
cognitive dysfunction in people with ADHD, as well as to
the modulation of cognition by psychostimulants and
noradrenaline reuptake inhibitors [17]. Here, we report the
results of predefined investigations into the long-term
effects of LDX on cognition, assessed using four CANTAB
tasks [DMS, SWM, SST and RTI].
2 Methods
2.1 Study Design and Conduct
SPD489-404 was a 2-year, phase IV, open-label safety
study of dose-optimised LDX in children and adolescents
with ADHD (ClinicalTrials.gov identifier: NCT01328756).
Full details of the study design, conduct, methods and
outcomes have been published previously [9].
The study was conducted in accordance with current
applicable international and national regulations and ethi-
cal requirements. Before participation, each patient’s par-
ent or legally authorised guardian provided informed
consent, and each patient provided assent, if applicable.
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The study protocol was approved by an independent ethics
committee/institutional review board and regulatory
agency in each centre (as appropriate). The study took
place at 35 sites in ten European countries (Belgium,
Germany, Hungary, Italy, the Netherlands, Poland,
Romania, Spain, Sweden and the UK) between July 2011
and September 2014.
2.2 Participants
Patients eligible to take part in the study were aged
6–17 years, were required to meet Diagnostic and Statis-
tical Manual of Mental Disorders, Fourth Edition—Text
Revision [18] criteria for a primary diagnosis of ADHD and
had to have an ADHD Rating Scale IV (ADHD-RS-IV
[19]) total score ofC 28 at the baseline visit. Patients who
had participated in one of the three previous LDX studies
[2, 20, 21] were excluded from the present study if they had
discontinued the previous study because of protocol non-
adherence or non-compliance, or if they had experienced a
clinically significant treatment-emergent adverse event or
adverse event that would preclude further exposure to
LDX. Participants were also excluded if their current
ADHD medication provided adequate control of ADHD
symptoms with acceptable tolerability. Other inclusion and
exclusion criteria have been reported previously [9].
Participants were not required to enter the present study
immediately from any of the previous studies. However,
patients with a gap of at least 7 days between exiting a
previous study and entering this study were required to
have a baseline ADHD-RS-IV total score ofC 28 to be
enrolled.
2.3 Study Drug Administration
Participants took once-daily morning doses of open-label
LDX during the 4-week dose-optimisation period and the
subsequent 100-week dose-maintenance period. During
dose optimisation, participants’ doses were actively titrated
to LDX 30, 50 or 70 mg/day, starting at 30 mg/day and
increasing or decreasing in weekly 20-mg steps until an
acceptable response was achieved. An acceptable response
was defined as a reduction ofC 30% in ADHD-RS-IV total
score from baseline with a Clinical Global Impressions-
Improvement [22] score of 1 or 2 and tolerable side effects.
Dose adjustments were also permitted, if necessary, during
the dose-maintenance period. All doses ranged from a
minimum of 30 mg/day to a maximum of 70 mg/day.
2.4 Neuropsychological Tasks and Testing
Cognitive function was assessed at baseline (week 0), at
weeks 4, 24, 48, 72 and 104 of the open-label treatment
period and/or at the early termination visit (Fig. 1). Patients
were also assessed at a subsequent safety follow-up visit
(28–30 days following the last dose of LDX; data not
presented). Four neuropsychological tasks from CANTAB
were selected to assess cognition: DMS, SWM, SST and
RTI (Table 1). DMS, SWM and SST were considered to be
the most relevant tasks with which to capture the key
cognitive domains implicated in the pathophysiology and
treatment of ADHD [17, 23, 24], and the RTI task has been
shown to be sensitive to potential deleterious effects [25].
Computerised tasks were administered using a touchscreen
device.
2.5 Neurocognitive Outcome Variables
and Statistical Analysis
Enrolment of about 300 patients was planned, but the
sample size of this open-label uncontrolled study was not
based on a statistical power calculation. The CANTAB
results were analysed for the safety population, defined as
all participants who received at least one dose of LDX
during the study, regardless of whether or not they com-
pleted the study.
For each of the four selected CANTAB tasks, key and
additional variables were pre-specified, based on recom-
mendations from Cambridge Cognition Ltd (Cambridge,
UK) (Table 1). Key variables were: per cent correct and
median reaction time on correct trials for DMS, total
between-search errors for SWM, stop signal reaction time
for SST, and simple median reaction time and 5-choice
median reaction time for RTI. The mean percentage change
from baseline at each on-treatment assessment was calcu-
lated as the mean change from baseline divided by the
mean at baseline in the safety population. No inferential
hypotheses were tested statistically for any of the SPD489-
404 safety outcomes, including the CANTAB outcomes
described here.
Given that there was no comparator arm in this study, a
threshold for potential clinical significance was predefined
as a groupwise change from baseline of± 5% in key
CANTAB variables. This threshold was based on previous
experience with the CANTAB tasks and published data
from a 4-year longitudinal study of cognition in 17 boys
with ADHD and 17 age-matched typically developing boys
[23]. Over 4 years, the mean per cent change from baseline
on SWM between-search errors in untreated boys with
ADHD was 40%, equating to an improvement of * 5%
per 6 months. Mean DMS per cent correct improved
by * 3% every 6 months. Stop Signal Task and RTI were
not assessed in this study.
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3 Results
3.1 Patient Disposition and Characteristics
Details of the study population have been published pre-
viously [9]. All 314 enrolled patients received at least one
dose of LDX and were included in the safety population.
Of these, 124 patients (39.5%) had participated in a pre-
vious LDX study [2, 20, 21] and 191 (60.8%) completed
the present study. The most common reasons for study
discontinuation were withdrawal by the participant (41/314
[13.1%]) and adverse events (39/314 [12.4%]). At baseline,
the patients had a mean age of 11.4 years (standard devi-
ation, 2.88 years), and 202/314 (64.3%) were children aged
6–12 years. Most participants were boys (250/314
[79.6%]) and nearly all were white (310/314 [98.7%]). The
mean ADHD-RS-IV total score at baseline was 41.1 (s-
tandard deviation, 7.03).
3.2 Delayed Matching to Sample (DMS)
No potentially clinically significant deterioration was seen
in the key DMS variables of per cent correct and median
reaction time on correct trials (i.e. a decrease in per cent
correct or an increase in time, respectively) (Fig. 2). The
mean DMS per cent correct remained close to the baseline
level throughout the study and at the last on-treatment
assessment (LOTA). The mean DMS per cent correct in all
trials with a delay, as well as simultaneous trials and trials
with a 0- or 12-s delay, generally remained close to base-
line levels at all subsequent study visits and at LOTA. In
trials with a 4-s delay, the mean per cent correct at LOTA
was below the baseline value.
For mean DMS median reaction time on correct trials,
improvements predefined as being potentially clinically
significant were seen after 6 months and maintained
throughout the study. Improvements in median reaction
time were more pronounced in simultaneous trials and in
trials with a delay of 0 s than in the more difficult trials
with delays of 4 or 12 s.
3.3 Spatial Working Memory (SWM)
No potentially clinically significant deterioration (indicated
by an increase in score) was observed in the SWM key
variable of total between-search errors (Fig. 3). By
6 months, improvements in SWM total between-search
errors exceeded the predefined threshold for potential
clinical significance, with a mean decrease from baseline of
22.8%. This improvement was maintained throughout the
study and a 32.6% mean decrease from baseline was
observed at LOTA. For the additional variables of
between-search errors for trials of six or eight tokens, mean
changes from baseline indicated improvements at weeks
4–104 and at LOTA. Between-search errors for trials of
four tokens were close to zero and there was little room for
improvement during the study.
3.4 Stop Signal Task (SST)
No potentially clinically significant deterioration (indicated
by an increase in reaction time) was observed in the SST
key variable of stop signal reaction time (Fig. 4). Poten-
tially clinically significant improvements in stop signal
reaction time were observed, with 18.9% and 25.7% mean
decreases from baseline at 6 months and at LOTA,
respectively. For the additional variable of reaction time
standard deviation on ‘go’ trials, mean changes from
baseline indicated improvement throughout the study.
3.5 Reaction Time (RTI)
No potentially clinically significant deterioration (indicated
by an increase in reaction time) was observed in the key
RTI variables of simple median reaction time and 5-choice
median reaction time (Fig. 5). Both key variables remained
close to baseline levels at all subsequent study visits and at
30 mg 
70 mg 
50 mg LDX 
Dose-optimization
period
Dose-maintenance
period 
Baseline
Screening
Safety
follow-up
Study week 
Study visit 
–6 to –1 1 2 3 3624124 48
–1 10 2 3 7654 14
60 72 84 96 104 108
8 211109 13/ET
Fig. 1 SPD489-404 study design. Cambridge Neuropsychological
Test Automated Battery (CANTAB) assessments were carried out at
baseline (week 0), at weeks 4, 24, 48, 72 and 104 of the open-label
treatment period and/or at the early termination (ET) visit. LDX
lisdexamfetamine dimesylate
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Table 1 Cambridge Neuropsychological Task Automated Battery (CANTAB) tasks used in SPD489-404
CANTAB
task
Domain of cognition Description Key
variables
Additional variables
Delayed
matching
to sample
(DMS)
Recognition memory and short-
term visual memory
The participant is shown a complex visual
pattern and must then select the matching
pattern from four similar patterns shown
simultaneously, or with a delay of 0, 4 or 12 s
after the sample is concealed and the choices
are revealed
Per cent
correcta
Per cent correct
(simultaneous)
Per cent correct (0-s
delay)
Per cent correct (4-s
delay)
Per cent correct (12-s
delay)
Per cent correct (all trials
excluding simultaneous)
Median
reaction
time on
correct
trialsb
Median reaction time on
correct trials
(simultaneous)
Median reaction time on
correct trials (0-s delay)
Median reaction time on
correct trials (4-s delay)
Median reaction time on
correct trials (12-s
delay)
Spatial
working
memory
(SWM)
Retention and manipulation of
visuospatial information, as well
as some aspects of executive
function
The participant is shown a number of square
‘boxes’ and must find a blue token in each
box. The number of boxes increases from four
to six and then to eight; the colour and
position of the boxes change from trial to trial
Total
between-
search
errorsc
Between-search errors
(four tokens)
Between-search errors
(six tokens)
Between-search errors
(eight tokens)
Stop signal
task (SST)
Response inhibition and mental
processing speed
The participant must respond to an arrow
pointing in one of two directions by pressing
the corresponding button, but must inhibit
their response if a sound is heard
Stop signal
reaction
timed
Reaction time SD on ‘go’
trials
Reaction
time
(RTI)
Motor and mental response speed
and some aspects of impulsivity
The participant must respond in one of a variety
of ways to the appearance of a yellow dot,
either in a single location or in one of five
possible locations. The participant is
encouraged to go faster on each series of trials
Simple
median
reaction
timee
Simple reaction time SD
Simple premature
response errors
5-choice
median
reaction
timef
5-choice reaction time SD
5-choice premature
response errors
SD standard deviation
aThe proportion of assessed trials (%) in which the participant responded correctly on their first attempt, for all trials (key variable) or for each of
the four trial types (additional variables). Higher values indicate better cognitive function
bThe median reaction time in assessed trials in which the participant responded correctly, for all trial types (key variable) or for each of the four
trial types (additional variables). Lower values indicate better cognitive function
cThe number of times the participant returned to a box in which a token had already been found, in all trials (key variable) or separately in trials
with four, six or eight tokens (additional variables). Lower values indicate better cognitive function
dThe time between ‘go’ and ‘stop’ stimuli at which the participant inhibited their response in 50% of trials (key variable) and its SD (additional
variable). Lower values indicate better cognitive function
eIn assessed trials with a single stimulus, the time between stimulus and correct response (key variable) and its SD (additional variable), and the
number of trials in which the participant responded prematurely (additional variable). Lower values indicate better cognitive function
fIn assessed trials with a stimulus in one of five possible locations, the time between stimulus and correct response (key variable) and its SD
(additional variable), and the number of trials in which the participant responded prematurely (additional variable). Lower values indicate better
cognitive function
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LOTA. For the additional variable of simple premature
response errors, small decreases from baseline were
observed at weeks 4–104 and at LOTA, suggesting
improvement. All other additional variables remained close
to baseline levels throughout the study.
4 Discussion
In this 2-year open-label study, LDX was well tolerated in
children and adolescents with ADHD, with a safety profile
consistent with that established in previous studies of up to
12 months’ duration; there were no new safety signals of
concern [1, 9]. No potentially clinically significant deteri-
orations from baseline were observed in any of the four
CANTAB tasks. In fact, there was some evidence for
potentially clinically significant improvements from base-
line in certain cognitive domains. However, as discussed
below, the lack of a comparator group limits interpretation
of these data.
The EMA has recommended that neurocognitive mea-
sures should be included in long-term studies of ADHD
medications. Several studies have demonstrated that indi-
viduals with ADHD can have impairments in the cognitive
domains of response inhibition, working memory, pro-
cessing speed and reaction time variability [12, 17, 26].
Furthermore, certain psychoactive agents are known to
impair cognition, including cannabis and benzodiazepines
[27, 28]; indeed, CANTAB assessments demonstrated that
cannabis users had significant impairments in the quality of
decision making and executive planning compared with
controls [27]. To this end, the primary goal of the CAN-
TAB assessments during this 2-year study was to detect
any potential deterioration in cognitive function. The pre-
sent study provides evidence that LDX treatment is not
associated with the deterioration of cognitive function in
children and adolescents with ADHD.
A potential positive impact of LDX on cognitive func-
tion was observed in the present study in attention and
short-term visual memory (measured by the DMS task). A
much larger improvement occurred in the domains of
response inhibition (measured by the SST task) and
working memory and strategy (measured by the SWM
task). In the absence of a placebo control group, it is not
possible to dissect drug-induced changes in performance in
cognitive tasks from natural improvement over time, or
improvement owing to practice effects. However, the speed
of improvements in SST stop signal reaction time and
SWM total between-search errors (mean changes of -
14.9% and - 15.7% from baseline to week 4, respectively)
is more rapid and larger than would be expected in the
absence of the drug in young people with ADHD [23], and
also occurred in parallel with rapid symptomatic
improvements during the first 4 weeks [9]. It is, however,
unclear whether the cognitive improvements observed in
this study caused the improvements in core ADHD
symptoms, or were themselves secondary to ADHD
symptomatic improvements (e.g. as a result of reduced
symptoms of hyperactivity and inattention), or if these two
aspects of functioning were independent of each other, as
has been suggested by previous work [29].
The underlying mechanism notwithstanding, response
inhibition is a key cognitive treatment target for ADHD,
and the data presented showing a possible positive effect of
LDX on this and other domains of executive function
warrant further well-controlled investigations. Stratifica-
tion by baseline demographics and clinical characteristics,
as well as dose-response effects of LDX and the effects of
discontinuation on CANTAB performance, are potential
areas of interest for future investigation.
While the present study was the first to assess cognitive
function in people receiving LDX, previous studies have
investigated the effects of alternative ADHD medications
on cognition. A meta-analysis of randomised controlled
trials found that the stimulant methylphenidate was sig-
nificantly more effective than placebo at improving cog-
nitive function in children and adolescents with ADHD in
acute challenge situations [30]. Methylphenidate treatment
was associated with improvements across all five neu-
ropsychological domains examined (executive memory,
non-executive memory, reaction time, reaction time vari-
ability and response inhibition). However, effect sizes for
neurocognitive outcomes were smaller than those reported
for improvements in ADHD symptom scores and no
studies of longer term methylphenidate use were included
in the analysis [30]. The non-stimulant ADHD treatment
atomoxetine has also been associated with improvements
in some aspects of cognitive function in children and
adolescents with ADHD, although the data are limited and
again relate only to acute challenge [24, 31].
A number of key limitations should be considered when
interpreting the findings presented here. First, the open-
label nature of the study and the lack of a control arm
preclude firm conclusions about the potential beneficial
effects of LDX. Change-from-baseline data are presented,
but the lack of adequate normative developmental data for
the CANTAB tasks across this age range makes it difficult
to distinguish between potential treatment benefits and
improvements relating to the normal development of
children and adolescents over a 2-year period. In particular,
a contribution of the natural developmental improvement
in symptoms (especially hyperactive/impulsive symptoms)
to the improvement in the SST stop signal reaction time
task cannot be excluded. Second, although the four CAN-
TAB tasks used in this study were selected to evaluate
potential cognitive effects of stimulant treatment in
D. R. Coghill et al.
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children and adolescents with ADHD, LDX may have
affected cognitive function in domains that were not tested.
Third, because data were analysed at the group level only,
potentially clinically significant changes in individual
patients’ cognitive function were not examined. Finally,
the response rate of about 60% observed in this clinical
trial setting is higher than might be expected in clinical
practice, suggesting that the observed improvements in
CANTAB may also exceed those seen routinely by
physicians.
Important strengths of SPD489-404 are the 2-year
duration, the inclusion of a large number of participants
bFig. 2 Delayed Matching to Sample outcomes: a, b key and c,
d additional variables. Dashed lines indicate the mean at baseline
(week 0). Arrows show the direction of improvement; higher per cent
correct and lower median reaction time indicate better cognitive
function. Annotated percentages indicate potentially clinically sig-
nificant changes from baseline (key variables only; parts a and b).
Groupwise summary data are shown in Online Resource 1. LOTA last
on-treatment assessment, SD standard deviation
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direction of improvement; lower reaction time and lower reaction
time standard deviation (SD) on ‘go’ trials indicate better cognitive
function. Annotated percentages indicate potentially clinically sig-
nificant changes from baseline (key variable only; part a). Groupwise
summary data are shown in Online Resource 3. LOTA last on-
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from multiple centres in European countries and the
inclusion of the CANTAB to assess cognition. The CAN-
TAB tasks have proven congruence with traditional neu-
ropsychological tasks and are an accepted and validated
measure of cognitive function in patients with ADHD [32].
The CANTAB includes several different tasks with sensi-
tivity to particular types of neurocognitive dysfunction.
Furthermore, because the tasks are computerised, the
CANTAB benefits from reliability of administration and
practice effects are minimised by the use of parallel ver-
sions across all testing sessions. Additionally, the inclusion
of multiple difficulty levels in the SWM and DMS allows
any ceiling or floor effects to be identified [33].
5 Conclusion
This 2-year study provides evidence that LDX treatment is
not associated with cognitive impairment in children and
adolescents with ADHD, and suggests that potential long-
term cognitive function improvements may be worthy of
further investigation in well-controlled studies.
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